期刊文献+

人突变CD59基因在卵巢癌细胞表达及其生物活性检测

EXPRESSION OF MUTANT CD59 GENE IN OVARIAN CANCER CELLS AND ITS ACTIVITY DETECTION
下载PDF
导出
摘要 目的研究野生型CD59与突变型CD59在卵巢癌细胞A2780表面的抗补体活性。方法取突变型CD59质粒、野生型CD59质粒分别转染A2780细胞,G418筛选稳定表达细胞克隆;酶免疫法及RT-PCR方法检测细胞表面CD59蛋白及mRNA的表达;制备抗CD59多克隆抗体,MTT法观察CD59蛋白的抗补体活性。结果野生型及突变型CD59质粒扩增成功,并成功建立了稳定转染野生型和突变型CD59的A2780细胞株;与野生型CD59相比,突变型CD59失去对补体的抑制功能,与未转染A2780表面CD59表达无显著差异。结论CD59的W40位点对其功能具有重要作用,封闭该位点能够提高补体溶细胞作用,有望应用于肿瘤治疗。 Objective To study the antieomplementary activity (ACA) of wide-type CD59 and mutant CD59 On ovarian cancer A2780 cells. Methods The pires-WTCD59 plasmid and the pires M1CD59 plasmid were transfected into A2780 cells. Stable expression clones were selected by the addition of G418. Immunohistochemistry method and RT PCR were used to analyze the quantity of protein CD59. The ACA of CD59 was tested by MTT method, Results The pires-WTCD59 plasmid and the pires-MICD59 plasmid were successfully amplified. A2780 cells with pires-WTCD59 and cells with M1CD59 were selected. The re suits suggested that mutant CD59 lost its protection of being against human complement compared with WTCD59. There was no significant difference compared with CD59 on A2780 cells. Conclusion The W40 of human CD59 is important to its activity, prohibition of this site may be a potential way to raise complement activity and treat tumor.
出处 《青岛大学医学院学报》 CAS 2009年第4期313-315,318,共4页 Acta Academiae Medicinae Qingdao Universitatis
基金 国家自然科学基金资助项目(30170893)
关键词 抗原 CD59 卵巢肿瘤 基因 突变 Antigen, CD59 Ovarian neoplasms Gene Mutation
  • 相关文献

参考文献11

二级参考文献63

  • 1罗师平,冷希岗.基于PCR的体外诱变技术[J].国外医学(生物医学工程分册),2005,28(3):188-192. 被引量:25
  • 2高美华,王秋波,张艳丽,任书荣,王静.人突变CD59基因表达蛋白功能的研究[J].青岛大学医学院学报,2005,41(3):220-222. 被引量:4
  • 3程颖,高美华.利用噬菌体肽库筛选与人CD59特异性结合的短肽[J].细胞与分子免疫学杂志,2006,22(2):164-166. 被引量:10
  • 4徐芳,姚泉洪,熊爱生,彭日荷,侯喜林,曹兵.重叠延伸PCR技术及其在基因工程上的应用[J].分子植物育种,2006,4(5):747-750. 被引量:45
  • 5MARK J S,DALE I G,JOSEPH A T.A fresh look at tumor immunosurveillance and immunotherapy[J].Nature Immunology,2001,9(4):293-299.
  • 6GAVIN P D,LIOYD J O,ROBERT D S.The immunobiology of cancer immunosurveillance and immunoediting[J].Immunity,2004,21:137-148.
  • 7FISHEISON Z,DONIN N,ZELL S,et al.Obstacles to cancer immunotherapy:expression of membrane complement regulatory proteins (mCRPs) in tumors[J].Mol Immunol,2003,40(2/4):109-123.
  • 8DE N C,FONSATTI E,SIGALOTTI L,et al.Recombinant transmembrane CD59 (CD59-TM) confers complement resis-tance to GPI-anchored protein defective melanoma cells[J].J Cell Physiol,2002,190(2):200-206.
  • 9金冬雁译.分子克隆实验指南[M].第2版.北京:科学出版社,1995:5-57,870-898.
  • 10BABIKER A A,NILSSON B,RONQUIST G,et al.Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack[J].Prostate,2005,62(2):105-114.

共引文献322

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部